ArticleMolecular cancer2026
CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crosstalk between alternative splicing and non-coding RNAs in hepatocellular carcinoma: from regulatory mechanism to therapeutic implications.Non-coding RNA research · 2026Review
- Hub circRNAs in cancer: dual regulation of metastasis and immune evasion.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is the most malignant BC subtype, and metastasis remains the major cause of poor prognosis. TGF-β plays crucial roles in TNBC metastasis, yet the underlying mechanisms remain unclear. Circular RNAs (circRNAs) are a novel type of regulatory RNA characterized by high evolutionary conservation and stability. This study aims to investigate the roles and mechanisms of circRNAs in TGF-β-induced TNBC metastasis.
methodsCircNSD2 was detected in TNBC cells through high-throughput RNA sequencing. Gain- and loss-of-function assays were performed to evaluate the role of circNSD2. Chromatin immunoprecipitation (ChIP) and luciferase assays verified the regulatory effects of TGF-β on circNSD2. RNA pulldown, proteomic analyses, and RNA immunoprecipitation were conducted to identify the downstream targets of circNSD2.
resultsCircNSD2 expression was upregulated in patients with metastatic TNBC and correlated with an unfavorable prognosis. In vitro and in vivo studies indicated that circNSD2 facilitates TGF-β-induced TNBC metastasis and EMT. Mechanistically, circNSD2 is activated by TGF-β and cyclized by KHSRP. Moreover, circNSD2 functions as a scaffold to enhance the interaction between the SRSF6 and USP10 proteins, thereby preventing K48-linked polyubiquitination of SRSF6 at lysine 16 and inhibiting its proteasomal degradation. Furthermore, stabilized SRSF6 reprogrammed TPM1 alternative splicing, which resulted in TNBC metastasis. In addition, circNSD2 promoted immune escape in TNBC by upregulating PD-L1 expression and suppressing the antitumor immunity of CD8+ T cells.
conclusionOur study revealed that circNSD2 increased TNBC metastasis and immune escape by promoting the USP10/SRSF6/TPM1 axis and that circNSD2 could serve as a potential diagnostic biomarker and therapeutic target for TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.